Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma

Facon, Thierry, Kumar, Shaji, Plesner, Torben, Orlowski, Robert Z., Moreau, Philippe, Bahlis, Nizar, Basu, Supratik, Nahi, Hareth, Hulin, Cyrille, Quach, Hang, Goldschmidt, Hartmut, O’Dwyer, Michael, Perrot, Aurore, Venner, Christopher P., Weisel, Katja, Mace, Joseph R., Raje, Noopur, Attal, Michel, Tiab, Mourad, Macro, Margaret, Frenzel, Laurent, Leleu, Xavier, Ahmadi, Tahamtan, Chiu, Christopher, Wang, Jianping, Van Rampelbergh, Rian, Uhlar, Clarissa M., Kobos, Rachel, Qi, Ming, Usmani, Saad Z.·2019·New England Journal of Medicine
DOI 10.1056/nejmoa1817249

Cited by (1,013)

Items 701–800 of 1,013

  1. Use of daratumumab in therapy of patients with newly diagnosed multiple myeloma complicated by dialysis-dependent kidney failure: literature review and clinical observation
    Yu. E. Ryabukhina, Pervin A. Zeynalova, О. Л. Тимофеева, F. M. Abbasbeyli, Timur Teimurazovich Valiev, Купрышина Наталья Александровна · 2023 · MD-Onco
  2. Real-world multiple myeloma risk factors and outcomes by non-Hispanic Black/African American and non- Hispanic White race/ethnicity in the United States
    Tondre Buck, Monique A. Hartley-Brown, Yvonne Adeduni Efebera · 2023 · Haematologica
  3. Hämatologische Neoplasien und solide Tumore
    Wolf-Dieter Ludwig, Arnold Ganser, Georg Maschmeyer · 2023 · Springer eBooks
  4. Efficacy of daratumumab in newly diagnosed multiple myeloma patients with 1q21 gain
    Hirono Iriuchishima, Akio Saito, Masahiro Mihara · 2024 · International Journal of Hematology
  5. The emerging role of melflufen and peptide-conjugates in multiple myeloma
    Nour M. Moukalled, Iman Abou Dalle, Jean El Cheikh, Yishan Ye, Florent Malarad, Mohamad Mohty, Ali A. Bazarbachi · 2024 · Current Opinion in Oncology
  6. Comparative analysis of single versus tandem autologous stem cell transplantation in patients with multiple myeloma in Korea: the KMM2102 study
    Jongheon Jung, Sung‐Hoon Jung, Je‐Jung Lee, Young Rok Do, Ka‐Won Kang, Jung Lim Lee, Sung‐Soo Yoon, Chang‐Ki Min, Hye Jin Kang, Ji Hyun Lee et al. · 2024 · Scientific Reports
  7. Revealing the Therapeutic Potential of Stem Cells in Burn Healing: A Deeper Understanding of the Therapeutic Mechanisms of Epidermal Stem Cells and Mesenchymal Stem Cells
    Jianyu Lu, Wei Zhang, Yushu Zhu, Pengfei Luo, Xirui Tong, Sujie Xie, Luofeng Jiang, Xinya Guo, Jie Huang, Minyi Gu et al. · 2024 · Stem Cells International
  8. Relative Dose Intensity of Daratumumab, Lenalidomide, and Dexamethasone in Multiple Myeloma
    Kazuhito Suzuki, Tadahiro Gunji, M. Kawashima · 2025 · Cancers
  9. High‐risk features of early relapse in newly‐diagnosed multiple myeloma: The impact of cytogenetics and response to initial therapy
    Andrea Manubens, Bruno Paiva, Norma Carmen Gutierrez, Manuela Fernández, Marı́a José Calasanz, Laura Rosiñol, Albert Oriol, María Jesús Blanchard, Estrella Carrillo, Celina Benavente et al. · 2025 · HemaSphere
  10. Pomalidomide, Cyclophosphamide, and Dexamethasone for Relapsed/Refractory Multiple Myeloma: A Single-Center Experience
    Ioannis Ntanasis‐Stathopoulos, Panagiotis Malandrakis, Charalampos Filippatos, Sotirios Maganas, Despina Fotiou, Foteini Theodorakakou, Vasiliki Spiliopoulou, Nikolaos Kanellias, Magdalini Migkou, Evangelos Eleutherakis‐Papaiakovou et al. · 2025 · Clinical Lymphoma Myeloma & Leukemia
  11. Evolution of diagnostic workup and treatment for multiple myeloma 2013‐2019
    Fredrik Hellem Schjesvold · 2020 · European Journal Of Haematology
  12. Hematological and infectious complications with CD38 antigen targeting monoclonal antibody-based therapies in multiple myeloma: A meta-analysis of randomized control trials
    Naveen Yarlagadda, Sravani Gundarlapalli, Smriti Sharma · 2021 · Leukemia Research
  13. Treatment of multiple myeloma in 2021
    Jiří Minařík · 2021 · Klinická farmakologie a farmacie
  14. Emerging Role of Antibody-Drug Conjugates and Bispecific Antibodies for the Treatment of Multiple Myeloma
    Waqqas Tai, Ahsan Wahab, Diana Franco, Zunairah Shah, Aqsa Ashraf, Qurrat‐ul‐ain Abid, Yaqub Nadeem Mohammed, Darshan Lal, Faiz Anwer · 2022 · Antibodies
  15. Quadruplets come of age for newly diagnosed multiple myeloma
    Manisha Bhutani, Saad Z. Usmani · 2019 · The Lancet
  16. Intensification and consolidation therapy in multiple myeloma in the current era
    Omar Nadeem, Irene M. Ghobrial · 2020 · The Lancet Haematology
  17. Current and future perspectives of maintenance therapy in multiple myeloma
    Chandramouli Nagarajan, Melinda Si Yun Tan, Yunxin Chen, Giovanni Martinelli, Claudio Cerchione · 2021 · Panminerva Medica
  18. Optimizing the Outcome of Anti-Myeloma Treatment with Daratumumab
    Torben Plesner · 2021 · Journal of Clinical Medicine
  19. Emerging and current treatment combinations for transplant-ineligible multiple myeloma patients
    Paola Tacchetti, Serena Rocchi, Simona Barbato, Elena Zamagni, Lucia Pantani, Katia Mancuso, Ilaria Rizzello, Michèle Cavo · 2021 · Expert Review of Hematology
  20. Minimal Residual Disease in Multiple Myeloma: an Important Tool in Clinical Trials
    Alessandro Gozzetti, Monica Bocchia · 2021 · Reviews on Recent Clinical Trials
  21. CyBorD-DARA in Newly Diagnosed Transplant-Eligible Multiple Myeloma: Results from the 16-BCNI-001/CTRIAL-IE 16-02 Study Show High Rates of MRD Negativity at End of Treatment
    Dawn Swan, Robert B. Henderson, Cian McEllistrim, Serika D. Naicker, John Quinn, Mary R. Cahill, Vitaliy Mykytiv, Elizabeth Lenihan, Emer Mulvaney, Marc Nolan et al. · 2022 · Clinical Lymphoma Myeloma & Leukemia
  22. Pulmonary tuberculosis infection and CMV reactivation following daratumumab treatment in a patient with relapsed plasmablastic lymphoma
    Wenyue Cao, Yuling Wan, Xingcheng Yang · 2022 · Blood Science
  23. Real-world Outcomes With Cumulative Bortezomib Dose and Efficacy in the Treatment of Transplant-ineligible Multiple Myeloma With Cyclophosphamide, Bortezomib, and Dexamethasone
    Chunpeng Nie, Holly Lee, Jason Tay, Peter Raymond Duggan, Sylvia McCulloch, Paola E. Neri, Nizar Jacques Bahlis, Victor Hugo Jimenez-Zepeda · 2022 · Clinical Lymphoma Myeloma & Leukemia
  24. Tumor immunology
    Pouya Mahdavi Sharif, Amin Pastaki Khoshbin, Elaheh Nasrollahzadeh, Mahsa Keshavarz‐Fathi, Nima Rezaei · 2023 · Elsevier eBooks
  25. First-line treatment of multiple myeloma in both transplant and non-transplant candidates
    Albert Oriol, Laura Abril, Gladys Ibarra · 2023 · Expert Review of Anticancer Therapy
  26. Is less always more? Emerging treatment concepts in geriatric hemato-oncology
    Nina Rosa Neuendorff, Hans Christian Reinhardt, Konstantinos Christofyllakis · 2023 · Ageing and Cancer Research & Treatment
  27. Acute hypoxic respiratory failure due to Lenalidomide-induced interstitial pneumonitis in a patient with multiple myeloma
    Kyle O’Meara, Kush M. Fansiwala, Nikhita Kathuria‐Prakash, Monica El‐Masry, Scott Oh · 2024 · BMC Pulmonary Medicine
  28. Management of newly diagnosed transplant ineligible multiple myeloma
    Shebli Atrash, Manisha Bhutani, Barry A. Paul, Peter Michael Voorhees, Saad Z. Usmani · 2020 · Leukemia & lymphoma/Leukemia and lymphoma
  29. A phase 1b study of once‐weekly carfilzomib combined with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma
    Melissa Alsina, Ola Landgren, Noopur S Raje, Rubén Niesvizky, William Bensinger, Jesús G. Berdeja, Tibor J. Kovacsovics, David H. Vesole, Belle Fang, Amy Sarah Kimball et al. · 2020 · American Journal of Hematology
  30. Immunotherapy with Antibodies in Multiple Myeloma: Monoclonals, Bispecifics, and Immunoconjugates
    Christie P.M. Verkleij, Wassilis S.C. Bruins, Sonja Zweegman, Niels W.C.J. van de Donk · 2021 · Hemato
  31. Updates in the management of relapsed/refractory multiple myeloma
    Kirollos S. Hanna, Samantha Larson, Jenny M. Nguyen, Sarah Tu, Jenna Boudreau, Sarah Rose · 2021 · Journal of Oncology Pharmacy Practice
  32. “I took the road less traveled, and that has made all the difference”: Making a case for high‐dose therapy and autologous stem cell transplantation in elderly patients with newly diagnosed multiple myeloma
    Ajay K. Nooka, Nisha S. Joseph, Sagar Lonial · 2021 · Cancer
  33. Daratumumab
    Vishnu Gopal, Biswajit Dubashi · 2020 · Indian Journal of Medical and Paediatric Oncology
  34. CD38 biallelic loss is a recurrent mechanism of resistance to anti-CD38 antibodies in multiple myeloma
    Benjamin T. Diamond, Linda Banovic Baughn, Mansour Poorebrahim, Alexandra Maria Poos, Holly Lee, Marcella Kaddoura, Julia Erin Wiedmeier, Michael A. Durante, Gregory E. Otteson, Dragan Jevremović et al. · 2024 · bioRxiv (Cold Spring Harbor Laboratory)
  35. Développements thérapeutiques en hématologie au XXIe siècle
    Norbert Claude Gorin · 2022 · Bulletin de l Académie Nationale de Médecine
  36. Principles of prevention and management of adverse events of immunomodulatory drugs in the treatment of multiple myeloma
    Grzegorz Charliński, David H. Vesole, Artur J. Jurczyszyn · 2022 · Nowotwory Journal of Oncology
  37. Role of flow cytometric measurable residual disease assessment in multiple myeloma
    Agnieszka Krzywdzińska, Bartosz Puła, Krzysztof Jamroziak · 2023 · Acta Haematologica Polonica
  38. At what point are we on the way to optimally treat multiple myeloma patients over 75 years of age in 2023?
    Agata Tyczyńska, Jan Maciej Zaucha · 2023 · Advances in Clinical and Experimental Medicine
  39. Tinostamustine (EDO-S101), an Alkylating Deacetylase Inhibitor, Enhances the Efficacy of Daratumumab in Multiple Myeloma by Upregulation of CD38 and NKG2D Ligands
    Andrea Díaz-Tejedor, Javier Rodríguez‐Ubreva, Laura Ciudad et al. · 2024 · International Journal of Molecular Sciences
  40. Cost-Minimization Analysis for Subcutaneous Daratumumab in the Treatment of Newly Diagnosed Multiple Myeloma in Three Gulf Countries
    Anas Ahmad Hamad, Shereen Elazzazy, Ruba Yasin Taha et al. · 2024 · Journal of health economics and outcomes research
  41. Quadruplets in newly diagnosed transplant‐ineligible multiple myeloma
    Rajshekhar Chakraborty, Hira S. Mian · 2024 · American Journal of Hematology
  42. Unravelling Transplant-Ineligible Newly Diagnosed Multiple Myeloma Treatment in Real-World Practice in Spain: The CARINAE Study
    Felipe de Arriba, Mercedes Gironella, Miguel Teodoro Hernández Garcia, Juan Alfonso Soler Campos, Susana Herráez Rodríguez, María José Moreno Belmonte, Teresa Regueiro López, Miriam González-Pardo, María Casanova Espinosa, on behalf of the CARINAE Study Investigators · 2024 · Pharmaceuticals
  43. Pathological Fracture of Multiple Myeloma with CRAB Criteria: A Case Report
    Habib Burahman, Silvia Laelatus Sifa, Tabitha Puspaning Asmara · 2024 · Journal of Health and Nutrition Research
  44. Blurring the Lines: Beyond Using Transplant Eligibility to Guide Induction Therapy in Myeloma
    Darren Pan, Anupama Deepa Kumar, Alfred Chung, Ajai Chari · 2025 · The Hematologist
  45. Modeling MRD Changes in Myeloma to Understand Treatment Effects, Predict Outcomes, and Investigate Curative Potential
    Walter Martin Gregory, Thomas J. Prior, J. Blake Bartlett, Pieter Sonneveld, Meletios Athanasios Dimopoulos, Philippe Moreau, Saad Z. Usmani, Thierry T.F. Facon · 2025 · Clinical Cancer Research
  46. Daratumumab, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide, and Dexamethasone in Transplant‐Ineligible Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Meta‐Analysis
    Lucio Gordan, Rohan Medhekar, Alex Z. Fu et al. · 2025 · Hematological Oncology
  47. The efficacy of new drug regimens in treating newly diagnosed high-risk cytogenetic multiple myeloma patients: a systematic literature review and meta-analysis
    Huixing Zhou, Wen-Ming Chen · 2025 · Frontiers in Medicine
  48. Clinical Benefit of Early Daratumumab Use in Multiple Myeloma is Undefined
    Ruben Van Dijck, Zoran Erjavec, John‐John B. Schnog · 2025 · American Journal of Hematology
  49. Expression of Kappa Myeloma Antigen (KMA) and Lambda Myeloma Antigen (LMA) on Malignant but Not Normal Plasma Cells Offers Novel Therapeutic Targets for Patients With Myeloma, Amyloidosis and Other Plasma Cell Dyscrasias.
    M. Sartor, Thomas X Lemarchand, Luise Britz, J. Er, Simon Harrison, Rosanne Dunn, David J Gottlieb · 2025 · Clinical Lymphoma, Myeloma & Leukemia
  50. How the addition of selinexor/bortezomib/dexamethasone as a Category 1 recommendation may erode outcomes
    Zena Chahine, Tomer Meirson, Shai Gilboa, Ghulam Rehman Mohyuddin · 2025 · The Oncologist
  51. Prognostic Implications of Thrombocytopenia in Chinese Patients With Newly Diagnosed Multiple Myeloma
    Xiaojing Li, Xiaoxi Xu, Xiaohui Lai, Xiaolin Wang, Xin Liu, Xin Liu, Luqun Wang, Zi Sheng, Jun Peng, Ping Chen et al. · 2025 · Cancer Medicine
  52. A Large-Scale Analysis of Autologous Stem Cell Transplantation for Multiple Myeloma Patients Older than 65 Years
    Adolfo Sáez, Gema Hernandez-Ibarbu, Lucia Medina de Alba, Reyes Mas Babio, Andrea Tamayo, Ana Cuervo Fonseca, José María Sánchez‐Pina, Rafael Alberto Alonso Fernández, Nieves López‐Muñoz, Alberto Blanco Sánchez et al. · 2025 · Clinical Lymphoma Myeloma & Leukemia
  53. Lynozyfic (Linvoseltamab): A First‐in‐Class Off‐the‐Shelf T‐Cell Redirector for Refractory Multiple Myeloma
    Raza Ur Rehman · 2025 · eJHaem
  54. How to approach the high-risk myeloma from induction through relapse?
    Katja Christina Weisel, Christoph Schaefers, Lisa Beatrice Leypoldt · 2025 · Hematology
  55. Daratumumab induced lichenoid drug eruption
    Curtis Perz, Thomas S Wissman, Aubrey Montebello · 2026 · JAAD Case Reports
  56. Time and Resource Implications of Subcutaneous Daratumumab-Based versus Intravenous Isatuximab-Based Treatment Regimens for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant Ineligible
    Emma Smith, Alessandro Camera, Alex Bird · 2026 · Oncology and Therapy
  57. MRD ‐negative conversion with daratumumab monotherapy in newly diagnosed multiple myeloma patients in ≥ VGPR / MRD ‐positive after first‐line therapy: Final analysis of the open‐label, single‐arm multicentric phase 2 trial DART4MM
    Alessandro Gozzetti, Paola Pacelli, Federico Caroni, Donatella Raspadori, Elena Bestoso, Elisabetta Antonioli, Gabriele Buda, Sara Ciofini, Adele Santoni, Luca Puccetti et al. · 2026 · British Journal of Haematology
  58. Precision targeting of CD38 in immune thrombocytopenia: Mechanistic foundations and therapeutic implications
    Xin Zhou, Yubao Liu, Peipei Zhang, Ningning Shan · 2026 · European Journal of Pharmacology
  59. Renal recovery and clinical outcomes with daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma with severe renal impairment
    Yuichi Horigome, Hirotoshi Kamata, Koichi Ehata, Noriyuki Tadera, Kei Hayama, Takahiro Suzuki · 2026 · International Journal of Hematology
  60. Real-World Progression-Free Survival and Healthcare Resource Utilization Associated with Daratumumab Use in Transplant-Ineligible Multiple Myeloma Patients in Italy
    Valentina Perrone, Gregorio Barilà, Luca Franceschini, Giuseppe Mele, Stefania Mazzoni, Maria Laura Cappuccilli, Margherita Andretta, Marcello Bacca, Fausto Bartolini, Antonietta Barbieri et al. · 2026 · ClinicoEconomics and Outcomes Research
  61. BCMA/CD19 dual-targeting CAR T-cell therapy in older patients with newly diagnosed multiple myeloma: a phase 1 study
    Jin Liu, Xiaoqiang Fan, L. Peng, Jia Liu, Hai-Yan He, Wan-Ting Qiang, Lina Jin, Lang Shi, J. Lu, Pei Guo et al. · 2026 · Blood Advances
  62. Prognostic Impact of Chromosome 1q Gain/Amplification in Multiple Myeloma Treated With Daratumumab‐Based Regimens
    Emiliano Barbieri, Laura Arletti, Micol Quaresima et al. · 2026 · European Journal Of Haematology
  63. The safety profile of lenalidomide, dexamethasone, daratumumab, and bortezomib combinations in multiple myeloma: a retrospective analysis of the FAERS database
    Dandan Li, Qi Xiao, Zhijie Yu, Xi Zheng, Xinyue Hu, Yao He, Jianxing Zhou, Xiaoyuan Zheng · 2026 · Naunyn-Schmiedeberg s Archives of Pharmacology
  64. Recent and anticipated novel drug approvals (Q2 2026 through Q1 2027)
    Rachel Joseph, Michelle Sabbah, Farah Barada · 2026 · American Journal of Health-System Pharmacy
  65. Frontline daratumumab, lenalidomide, and dexamethasone in patients older than 80 years with newly diagnosed multiple myeloma: treatment durability, infectious complications, and nutritional vulnerability
    Yuichi Horigome, Koichi Ehata, Noriyuki Tadera · 2026 · Blood Research
  66. Subcutaneous delivery of daratumumab in Japanese patients with relapsed/refractory multiple myeloma
    Hirohiko Shibayama, Morio Matsumoto, Hiroshi Kosugi, Kazuhiro Shibayama, Hiroshi Yamazaki, Shinsuke Iida · 2020 · International Journal of Hematology
  67. The Modern Age of Monoclonal Antibodies: The Revolution of Daratumumab
    Gianfranco Lapietra, Francesca Fazio, Maria Teresa Petrucci · 2021 · IntechOpen eBooks
  68. An evaluation of isatuximab, pomalidomide and dexamethasone for adult patients with relapsed and refractory multiple myeloma
    Anna Piggin, Henry Miles Prince · 2021 · Expert Review of Hematology
  69. Strategies to Overcome High-Risk Multiple Myeloma
    Larysa Jessica Sanchez · 2021 · The Cancer Journal
  70. Addition by subtraction
    Sonja Zweegman, Tanya Marya Wildes · 2021 · Blood
  71. The evolving role and utility of off-label drug use in multiple myeloma
    James Hart Stoeckle, Faith E. Davies, Louis S. Williams, Eileen Mary Boyle, Gareth John Morgan · 2021 · Exploration of Targeted Anti-tumor Therapy
  72. Daratumumab for post-ASCT maintenance treatment of myeloma
    Prashant Kapoor, Shaji Kunnathu Kumar · 2021 · The Lancet Oncology
  73. Why Teaching Civic Engagement Is Essential.
    Dawn Reiss · 2012 · District administration
  74. Onkologika
    Wolf-Dieter Ludwig, Arnold Ganser, Georg Maschmeyer · 2021 · Springer eBooks
  75. Challenges and Opportunities to Access Innovation in Latin America: The Case of Combination Therapies for Multiple Myeloma
    Cristina Gutierrez Delgado, Virginia Abello, Martha Alvarado, Daniel Lew, Darı́o Londoño, Elizabeth McElwee, Mariana Rico-Restrepo, Natalia Paola Schutz, Stephen Doral Stefani, Ângelo Maiolino · 2022 · RAS Oncology & Therapy
  76. To transplant or not to transplant in multiple myeloma
    Richard LeBlanc · 2022 · Canadian Hematology Today
  77. Effectiveness of D-Rd program in the first line therapy of a 75-year-old female patient with multiple myeloma with high-risk cytogenetics. Clinical observation
    Yu. E. Ryabukhina, F. M. Abbasbeyli, Pervin A. Zeynalova, О. Л. Тимофеева, Купрышина Наталья Александровна, А. Г. Жуков · 2022 · MD-Onco
  78. Quercetin Targeting BIRC5 Inhibits the Proliferation of Glioblastoma and Affects the Prognosis Based on Bioinformatics and Network Pharmacology Analysis
    阳春 胡 · 2023 · Advances in Clinical Medicine
  79. Cytomegalovirus seropositivity is associated with improved responses to CD38 monoclonal antibody therapies in multiple myeloma: A single‐centre retrospective study
    Alex Yang Ge, Chiung‐Yu Huang, Rahul Kumar Banerjee et al. · 2023 · British Journal of Haematology
  80. Daratumumab-lenalidomide and daratumumab-pomalidomide in relapsed lenalidomide-exposed or refractory multiple myeloma
    Muhamad Alhaj Moustafa, Ricardo Daniel Parrondo, Mays F Abdulazeez, Vivek Roy, Taimur Sher, Victoria R. Alegria, Rahma M. Warsame, Rafaël Fonseca, Ahsan Rasheed, Wilson I. Gonsalves et al. · 2023 · Anti-Cancer Drugs
  81. Adjusting for subsequent therapies in the TOURMALINE-MM1 study shows clinically meaningful improvement in overall survival with addition of ixazomib to lenalidomide and dexamethasone
    Karthik Ramasamy, Nizar Jacques Bahlis, Shaji Kunnathu Kumar, Arun Kumar, Holly Cranmer, Bingxia Wang, Jonathan Dabora, Richard Labotka, Paul Gerard Guy Richardson, Philippe Moreau · 2024 · Haematologica
  82. Practical Aspects of Immunotherapy: A Report from the 20th International Myeloma Society (IMS) Annual Meeting
    Noopur S Raje, Adam D. Cohen, Krina K. Patel, Niels W.C.J. van de Donk, Joshua Ryan Richter, Jesús F. San Miguel · 2024 · Clinical Lymphoma Myeloma & Leukemia
  83. What Does the Phase III ‘IMROZ’ Study Mean for Patients with Multiple Myeloma? An Interview with the Co-authors
    2024 · EMJ Hematology
  84. The Outcome of Octogenarian Patients with Multiple Myeloma Treated Outside Clinical Studies, Focusing on Tolerability and Efficacy of Treatment
    Dana Amsterdam, Ori Grossberger, Natan Melamed, Dor Shpitzer, Svetlana Trestman, Tamir Shragai, Yael Chava Cohen, Irit Mazza Avivi · 2024 · Cancers
  85. The Real-World Outcomes of Relapsed/Refractory Multiple Myeloma Treated with Elotuzumab, Pomalidomide, and Dexamethasone
    Hitomi Nakayama, Yoshinobu Aisa, Chisako Ito · 2024 · Hematology Reports
  86. Is There a Role for Daratumumab Retreatment in Patients with Relapsed/Refractory Multiple Myeloma?
    Davor Galušić, Ivan Krečak, Viktor Blaslov, Krstulović Opara Anđela, Toni Valković, Sandra Bašić‐Kinda · 2025 · Biomedicines
  87. First relapse in older adults with multiple myeloma: Creating new pathways in uncharted territory
    Tanya Marya Wildes · 2025 · British Journal of Haematology
  88. Overview of 1q abnormalities in multiple myeloma: scientific opinions from Italian experts
    Mattia D’Agostino, Marina Martello, Lorenzo De Paoli, Silvia Mangiacavalli, Daniele Derudas, Francesca Fazio, Anna Furlan, Carmine Liberatore, Giuseppe Mele, Roberto Mina et al. · 2025 · Annals of Hematology
  89. Treatment of Multiple Myeloma in Patients Refractory to Daratumumab/Anti‐CD38 Monoclonal Antibodies: A Systematic Review
    Chia Jie Tan, Dylan Kacerek, Nattawara Kampirapawong, Amandeep Godara, Nathorn Chaiyakunapruk · 2025 · Cancer Medicine
  90. Current Strategy and Principles of Multiple Myeloma Treatment: A Literature Review
    Александр Сергеевич Лучинин, Anna Semenova, С. В. Семочкин · 2025 · Clinical oncohematology
  91. CAR-T-Cell Therapy: Success and Advancements in the Treatment of Hematological Malignancies
    Mahesh Bhaskar Hegde · 2025 · Springer eBooks
  92. Rising Unmet Need in Multiple Myeloma Management After First-Line Treatment With DRd: Expected Epidemiological Evolution in Italy
    Mario Boccadoro, Riccardo Mercati, Chiara Vassallo · 2025 · Clinical Lymphoma Myeloma & Leukemia
  93. Advances & future prospects in newly diagnosed multiple myeloma patients
    Issam S. Hamadeh, Shebli Atrash, Ashley Matusz Fisher, Maham Khan, Jordan Robinson, Barry Paul, Saad Z. Usmani · 2020 · Advances in Cell and Gene Therapy
  94. Pleural Involvement Upon Relapse of Myeloma Responding to Daratumumab Plus Carfilzomib: A Case Presentation and Literature Review
    Atilla Uslu, Güldane Cengiz Seval, Mustafa Merter, Klara Dalva, Meral Beksaç · 2020 · Clinical Lymphoma Myeloma & Leukemia
  95. Recommendations on the management of multiple myeloma in 2020
    Marie‐Christiane Vekemans, Chantal Doyen, Jo Caers, Kalung Wu, Alain Kentos, Philippe Mineur, Lucienne Michaux, Michel Delforge, Nathalie Meuleman · 2020 · Acta Clinica Belgica
  96. Induction Therapy Strategies in the Transplant-Ineligible Population
    Narsis Attar, Elizabeth O’Donnell · 2021 · The Cancer Journal
  97. Cross Fire: Daratumumab-Based Therapies Are Standard of Care in Newly Diagnosed Multiple Myeloma
    Neha Korde, Saad Z. Usmani · 2021 · Hematology/Oncology and Stem Cell Therapy
  98. Multicenter, phase II study of response-adapted lenalidomide-based therapy for transplant-ineligible patients with newly diagnosed multiple myeloma without high-risk features
    Kwai Han Yoo, Dok Hyun Yoon, Hye Jin Kang, Won Sik Lee, Kihyun Kım, Jin Seok Kim, Jeong‐A Kim, Sung‐Hyun Kim, Jae‐Yong Kwak, Yang Soo Kim et al. · 2021 · Current Problems in Cancer
  99. Daratumumab-based therapies in transplant-ineligible patients with untreated multiple myeloma and hepatic dysfunction: A systematic review of subgroup analyses
    Manuel David Gil‐Sierra, María Del Pilar Briceño-Casado, Silvia Fenix-Caballero, Emilio Jesús Alegre Del Rey, Catalina Alarcón de la Lastra‐Romero, Marina Sánchéz‐Hidalgo · 2021 · Journal of Oncology Pharmacy Practice
  100. Multiple Myeloma with a Special Focus on Precision Medicine
    Adrian Schmidt · 2020 · healthbook TIMES Oncology Hematology